Trial Profile
Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Melperone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2026.
- 03 Sep 2022 Planned End Date changed from 1 Dec 2018 to 1 Dec 2022.
- 31 Jul 2020 Status changed from active, no longer recruiting to completed, according to results published in the Blood